# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹745.8 Cr** FY26 (+17%) · **₹203.4 Cr** Q4 (+22% YoY / +18% QoQ) * **EBITDA:** **₹229.1 Cr** FY26 (+18%) · **₹63.2 Cr** Q4 (+39% YoY / +28% QoQ) * **EBITDA Margin:** **31%** FY26 (Flat) · **31%** Q4 (+380 bps YoY) * PAT: **₹1,736 Cr** FY26 (+30%) · **₹453 Mn** Q4 (+69% YoY / +5% QoQ) ## B. Revenue Growth & Market Dynamics * **Record Top-line Performance:** Achieved highest-ever quarterly and annual revenue, signaling a successful turnaround following a volatile prior fiscal year. * **Global Adoption Trends:** Growth was broad-based across all divisions, fueled by the structural macro shift toward wider enzyme adoption in pharma, nutraceutical, and biotech sectors. * **Product Momentum:** Quarterly performance was specifically bolstered by strong demand for **Serratiopeptidase**, contributing to robust sequential and year-over-year gains. ## C. Margins & Profitability Drivers * **Operating Leverage vs. Mix:** While EBITDA grew significantly due to volume-led operating leverage, gross margins faced a slight annual compression of **1%** due to a higher mix of lower-margin domestic sales. * **Strategic Pricing & Cost Management:** Management plans to implement price hikes in the **New Year** to offset rising costs; currently, the firm is prioritizing volume growth and customer acquisition over maximizing gross margins. * **Historical Margin Context:** Despite scaling significantly from post-COVID levels, the company has yet to return to historical **75%** gross margin peaks, currently stabilizing at the current levels to capture market share. * **One-off Adjustments:** Results were impacted by a **INR 16 Cr** litigation provision reversal, which was partially offset by new provisions for **Indian labor law** payroll impacts. ## D. Cash & Capital Allocation * **Balance Sheet Strength:** The company maintains a substantial cash reserve of approximately **INR 700 Cr**, with receivables remaining stable and consistent with historical credit terms. * **Shift in Distribution Strategy:** Management cancelled the interim dividend to evaluate more tax-efficient ways to reward shareholders, specifically citing a potential **share buyback** following recent regulatory changes. --- # 2. Segment & Product Performance ## A. Key Figures * **Human Healthcare:** **₹128.1 Cr** Q4 Revenue (+24% YoY) · **63%** Revenue Share (+15% FY Growth) * **Animal Healthcare:** **13%** Revenue Share (+19% Q4 YoY) · **25%** YTD Growth * **Specialized Manufacturing:** **9%** Revenue Share (+23% YTD Growth) * **Product Concentration:** **23%** Total Sales (Anti-inflammatory enzymes) · **23%** Revenue (Top 10 Customers) ## B. Segmental Dynamics & Innovation * **Strategic Pivot:** Robust momentum in Human and Animal nutrition stems from a deliberate shift toward **specialized, research-driven innovations** over commodity products. * **Bioprocessing Divergence:** Segment growth was led by a strong double-digit surge in the **food business**, while non-food performance remained stagnant. * **Capacity & Integration:** The company is leveraging a **500 cubic meter** fermentation capacity to transition into an integrated specialty bio-solution platform. * **Biocatalysis Outlook:** Despite some product-specific challenges, management expects moderate growth supported by ongoing trials for multiple new offerings. ## C. Core Product & Subsidiary Highlights * **Anti-Inflammatory Leadership:** Significant expansion in the Serratio business—driven by domestic market share gains—will lead to **restricted financial disclosures** hereafter to protect competitive positioning. * **Subsidiary Turnaround:** Evoxx successfully reversed prior losses to achieve a positive EBITDA of **₹7.2 Cr**, while Scitech maintained strong profitability with a **37%** EBITDA increase. * **Operational Efficiency:** Management utilized productivity improvements and increased output to successfully mitigate **pricing pressures** across the product mix. * **Probiotics Evolution:** Reported revenue declines in probiotics are misleading as the company shifts from commodity sales to **complex integrated formulations** that are harder to segregate. * **New Ventures:** **Staria** enters its first full year as an independent entity following a positive initial market reception. --- # 3. Manufacturing & R&D ## A. Key Figures * R&D Expenditure: ₹356 million standalone FY26 · 5.6% of consolidated Q4 revenue * **R&D CapEx:** **~₹130 Cr** total planned · **₹50 Cr** incremental current year * **Capacity Headroom:** **50%** immediate increase supported by existing infra * **IP Portfolio:** **15** active patents (following strategic pruning of non-revenue assets) ## B. Capacity & Expansion * **Infrastructure Readiness:** Management maintains significant operational flexibility with the ability to scale capacity **threefold** through phased expansion at the new R&D site. * **Strategic Optionality:** A final decision on main-plant expansion is slated for **post-September**, while a subsidiary-level capacity increment is already under consideration for the current fiscal. * **Rapid Implementation:** Prepared infrastructure allows for near-instantaneous scaling once expansion triggers are met, minimizing time-to-market for new volumes. ## C. Innovation & Patents * **High-Value Exclusivity:** Anticipated approval of a novel food product within the year could secure **exclusive supply rights** for up to a decade, marking a shift toward high-moat proprietary products. * **Strategic Pivot:** R&D focus is transitioning from service-oriented work to proprietary innovations, specifically targeting **peptide enzymes** and new chemistries. * **IP Lifecycle Management:** Recent patent count adjustments reflect a disciplined approach to ROI, retiring low-revenue legacy patents while filing **2-3 new applications** annually. ## D. R&D Infrastructure * **Next-Gen Facility:** The new Nashik center, set to be one of the industry's largest research hubs, is expected to be operational within **six months**. * **Operational Efficiency:** Despite the massive scale-up, R&D spending as a percentage of sales will remain stable due to **modern machinery** that reduces personnel-to-output ratios. * **Global Footprint:** The expansion complements existing domestic centers and the **Evoxx facility**, all of which will remain operational to support a diversified global innovation pipeline. * **Budgetary Outlook:** Revenue expenditure for R&D is projected to rise by **₹5 Cr**, reflecting the ramp-up of the new facility and increased product development bandwidth. --- # 4. Strategic Initiatives ## A. Global Market Strategy * **B. S. Pivot & Regulatory Focus:** Management is recalibrating its U.S. approach by prioritizing clinical studies and regulatory registrations to counter intensifying competitive pressures. * **Protein Segment Expansion:** The company is aggressively exploring the broader protein category, specifically monitoring fermentation-based non-meat proteins for future scaling. * **Competitive Positioning:** Economic volatility is being leveraged to capture market share from major incumbents like **Novonesis and Hansen** as customers seek alternative suppliers. * **Long-term Trust Advantage:** The firm is utilizing its **30- to 40-year track record** as a primary differentiator against European and Chinese rivals to secure long-term reliability. * **Strategic Shift:** Operations have transitioned from short-term margin protection to a global penetration strategy, integrating emerging technologies like **AI** into the innovation pipeline. ## B. Customer Base Evolution * **Market Share Prioritization:** Strategic focus has shifted toward securing customer traction and volume over immediate margin expansion to navigate the changing global landscape. * **Client Portfolio Diversification:** Efforts are underway to evolve the top 10 customer base while simultaneously increasing wallet share within long-standing accounts. * **B2B Pricing Sensitivity:** Management is balancing price adjustments against consumer affordability to prevent adverse impacts on total sales volumes in a competitive market. ## C. Operational Efficiency * **Productivity-Led Mitigation:** To counter inflationary pressures and limited pricing power, the company is focusing on internal cost reduction and productivity enhancements. * **Infrastructure Optimization:** Growth is being driven by optimized capacity allocation and a ramp-up in new product launches across both developed and emerging markets. * **Leadership Transition:** Following the exit of a long-time executive, responsibilities have been split between **two distinct heads** for the Indian and U.S. segments to ensure specialized focus. * **Organizational Continuity:** A multi-level management structure (second and third-line leadership) has been institutionalized to preserve stability during key personnel transitions. --- # 5. Geography & Market Mix ## A. Key Figures * **India Sales Growth:** **50%** Q4 YoY * **Revenue Mix (FY26):** **63%** Human Nutrition (Total) · **32%** India Domestic · **30%** International * **B. S. Revenue Growth:** **-11%** Q4 YoY (INR terms) * **U.S. Historical Performance:** **-6%** Revenue CAGR (Mar '22–Mar '24) · **22%** Currency Depreciation ## B. India Domestic Volume * **Volume-Led Expansion:** Robust top-line acceleration driven by volume gains across human nutraceutical, food, and animal feed segments rather than pricing. * **Pricing Stability:** Prices for key products like **Serratiopeptidase** remain steady following a period of intense competitive pressure. * **Revenue Integrity:** Management confirmed the recent surge in domestic performance was organic, excluding any one-time components or customer pre-buying. ## C. U.S. Market Transition * **Macroeconomic Headwinds:** High inflationary pressures and strained discretionary spending are expected to make the upcoming fiscal year highly challenging. * **Stabilization Outlook:** Management expects a shift from negative to flat-to-low growth, characterizing the U.S. as a long-term steady business despite recent revenue declines. * **Strategic Pivot:** The U.S. entity is undergoing a transition to align with shifting consumer habits, specifically targeting the rising **probiotics** and industrial food segments. * **Competitive Landscape:** Lack of growth since **2021** is attributed to a tough competitive environment and the need to adapt to rapid global nutraceutical trends. ## D. International Regulatory Approvals * **Pipeline Milestones:** Strategic filings include **two food enzyme dossiers** with the EFSA and **three** with the US FDA to bolster the international portfolio. * **European Expansion:** Secured EU approval for **Serratiopeptidase**, with additional anti-inflammatory product approvals anticipated shortly. --- # 6. Risks & External Factors ## A. Key Figures * Tariff Absorption: 10-odd percentage of costs currently absorbed by the company ## B. Inflationary Cost Pressures * **Margin Headwinds:** Rising input costs for fuel, salt, solvents, and logistics are exerting pressure on margins, particularly within energy-intensive operations. * **Operational Resilience:** Despite geopolitical disruptions and inflationary spikes, margins have been defended through R&D-led productivity gains and manufacturing output enhancements. * **Pricing Power Challenges:** High inflation in the U.S. across energy and food sectors is complicating the company's ability to pass through increased costs to the end consumer. ## C. Geopolitical & Supply Chain * **Strategic Stockpiling:** Inventory levels have been intentionally elevated to hedge against global supply chain uncertainties and prevent raw material stock-outs. * **Supply Reliability:** Management maintained a consistent delivery track record despite global trade restrictions and ongoing conflict-related disruptions. ## D. Regulatory & Tariff Uncertainty * **Tariff Management:** The company is utilizing a gradual pass-through strategy for the **10%** tariff burden to protect market share in a competitive B2B landscape. --- # 7. Guidance & Outlook ## A. Key Figures * **Growth Target:** **Double-digit** portfolio-wide (FY27) * **Margin Volatility:** **1% to 2%** expected variability range ## B. Growth Targets * **Resilient Top-line Strategy:** Management maintains a robust double-digit growth aspiration for FY27 by diversifying market drivers to counteract potential stagnation in high-margin U.S. regions. * **Domestic Momentum:** Indian market expansion is anchored by biocatalysis adoption and broadening applications across the pharmaceutical and food verticals. * **Portfolio-Level Focus:** Guidance has shifted toward aggregate portfolio performance rather than product-specific targets to account for multiple simultaneous growth initiatives. ## C. Margin Sustainability * **Profitability Retention:** Despite anticipated quarterly variability, the company expects to sustain the majority of recent gains within the core product run rate. * **Stability Outlook:** Management aims to hold margins steady with **FY26 levels**, viewing potential cost pressures as manageable within a narrow percentage range. * **Macro Resilience:** The FY27 outlook assumes steady margins despite external headwinds related to global energy price volatility and economic uncertainty. ## D. Future Pipeline Strategy * **Strategic Non-Disclosure:** The company will no longer provide granular R&D pipeline updates to mitigate competitive risks and preserve tactical flexibility.